Showing 241-250 of 9369 results for "".
Key Components of an Effective Strategic Plan
https://practicaldermatology.com/topics/practice-management/key-components-of-an-effective-strategic-plan/23933/A number of actionable steps can effectively and efficiently ensure that your practice stays on track.A Dermatologist’s Guide to Marketing Skin Cancer Screenings
https://practicaldermatology.com/topics/practice-management/a-dermatologists-guide-to-marketing-skin-cancer-screenings/23932/As the mercury soars, bring prevention and professional skin checks out of the shadows and into the light.At Your Service: Championing Employee Leadership
https://practicaldermatology.com/topics/practice-management/at-your-service-championing-employee-leadership/23793/How to develop engaged staff members who perform at the owner level.DermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)Estrogen and Skin: What Can We Do
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/estrogen-and-skin-what-can-we-do/20123/There’s accumulated evidence that depletion of estrogen with age contributes to the visible signs of skin aging. But dermatologists haven’t had many treatment options—until now. Joel L. Cohen, MD addresses the latest developments in care for estrogen deficient skin.Top Tips for Increasing Social Media Engagement
https://practicaldermatology.com/topics/practice-management/top-tips-for-increasing-social-media-engagement/23709/It takes time to grow your base, but if you know your audience and strategize, you can see gains.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyCosmetic Surgery Forum: 2021 Recap
https://practicaldermatology.com/topics/skin-cancer-photoprotection/cosmetic-surgery-forum-2021-recap/20032/Cosmetic Surgery Forum founder and director Joel Schlessinger, MD offers an overview of the 2021 conference in Nashville.DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesDermWireTV: Staff Vaccinations, Dupilumab Data, Rosacea Resource, Sensitive Skin Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-staff-vaccinations-dupilumab-data-rosacea-resource-sensitive-skin-week/19907/Most physicians have had a chance to be vaccinated, but staff may be a different story. Some practices are struggling with policies for mandated staff vaccines. The National Rosacea Society has updated its most popular educational booklet, “Understanding Rosacea.” New data highlight the potential im